Cross-Border Impact Ventures’ Post

On this International Women’s Day, we recognize the urgent need to close the gender gap in health outcomes—and celebrate the people working to make that a reality. At Cross-Border Impact Ventures, we are committed to closing these gaps by backing visionary companies that are transforming the landscape of women’s health.   Today, we want to highlight some of the incredible companies in our portfolio that are leading the charge in advancing gender equity in health:   Pendulum Systems uses artificial intelligence and machine learning to forecast healthcare demand to reduce wastage and stockouts of essential medicine and healthcare supplies.   Daye is a gynecological care provider focused on novel digital and physical products and diagnostics with the aim of eliminating the pain, shame, and inconvenience that is pervasive in care-seeking experiences for gynae health.   mOm Incubators has developed an affordable, collapsible, lightweight incubator that provides thermoregulation for newborns in order to prevent unnecessary NICU admissions, as well as providing care for babies in fragile contexts, ensuring consistent care and enabling safe relocation when necessary.   OncoLens is a digital health platform solving major and growing pain points in cancer care delivery by providing innovative oncology care management solutions to cancer patients and healthcare providers.   Sonio (exited) has developed an AI-enabled software company aiming to empower fetal ultrasound practitioners, bringing real time access to expert knowledge, improving security and quality on ultrasound exams, simplifying workflows and improving productivity.   Raydiant Oximetry, Inc. is addressing multiple unmet needs in maternal-fetal medicine, particularly emergency C-sections, newborn injury, and postpartum hemorrhage (PPH).   Axena Health is improving access and affordability to at-home pelvic floor disorder treatment for women through the Leva® Pelvic Health System.   Oxford Cancer Analytics has developed minimally invasive liquid biopsy tests that are affordable and scalable in any diagnostic facility worldwide so that early cancer detection tests can be accessed by those who need it the most.   Cardiosense is combining non-invasive physiological sensors and artificial intelligence for the detection, prediction, and management of cardiovascular disease.   We are so proud to support these companies as they do this important work towards a future where access, innovation, and equity in healthcare are no longer barriers for women and children to access quality healthcare. To all the entrepreneurs, funders, investors, researchers, and advocates working tirelessly to close the women’s health gap—thank you. Your work is driving impact, and we are honored to stand with you in this mission.   #IWD2025 #WomensHealth #ImpactInvesting